Article 76 of the Fourth Amendment1 to the Chinese Patent Law links regulatory approval of a generic drug and patent protection of the brand-name drug. It establishes a legal framework similar to the Hatch-Waxman Act in the United States for resolving drug patent disputes before approval of the generic drug product.
Under Article 76, when filing a New Drug Application (NDA), a patent holder must submit a Patent Registration Form to the Drug Patent Information Registration Platform2 maintained by the Center for Drug Evaluation (CDE) of the National Medical Products administration (NMPA). In turn, a generic drug applicant seeking marketing authorization of a generic version of the branded drug must submit one of the four types of certifications against each listed patent:
Type I: No relevant patent is listed on the Patent Registration Platform;
Type II: The relevant listed patent has expired or was invalidated;
Type III: The generic drug product will not enter the market before the expiration of the relevant listed patent; and
Type IV: The generic applicant believes the relevant listed patent to be invalid or not infringed.
If the generic applicant files a Type IV Patent Certification, asserting the relevant listed patent is invalid and/or will not be infringed by the generic applicant’s drug product, the patent holder may institute a civil judicial infringement proceeding against the generic applicant in (1) the IP courts; (2) special IP tribunals in local courts; and/or (3) administrative adjudications in the China National Intellectual Property Administration (CNIPA).
In April of 2022 – less than a year since Article 76 became effective – pharmaceutical companies have swiftly turned to these new venues for patent dispute resolution, and both the Beijing IP court and CNIPA have quickly resolved disputes between brand-name and generic companies under Article 76. The court and the CNIPA made these decisions well within the requisite 9-month stay period for marketing authorization approval, at a pace much faster than Hatch-Waxman litigation in U.S. district courts.
Article 76 litigation Before the Beijing IP Court
The first patent linkage case resolved under Article 76 since the enactment of the Fourth Amendment is Chugai Pharmaceutical Co. Ltd. v. Wenzhou Haihe Pharmaceutical Co., Ltd. (“Haihe”). In that case, the Beijing IP court held the generic drug manufactured by Haihe does not fall in the scope of patent protection of CN1938034B, owned by Chugai Pharmaceutical Co. Ltd. (aka, Sino-Foreign Pharmaceutical Co., Ltd.), and as such, Haihe does not infringe the patent.
The CN1938034B3 patent covers the aidecalcidol soft capsules drug product used to treat osteoporosis which is marketed by Chugai. Chugai registered the patent in the Patent Information Registration Platform as required by Article 76, and Haihe submitted a generic drug application for aidecalcidol soft capsules with a Type IV certification, asserting it does not infringe CN1938034B.
On November 10, 2021, Chugai timely filed an Article 76 suit with the Beijing IP court, asking the court to declare that Haihe’s generic drug product infringes CN1938034B. On April 15, 2022, the Beijing IP court handed the generic company a victory, holding Haihe does not infringe CN1938034B because Haihe’s generic drug product is neither the same as nor equivalent to the technical solution used to prepare Chugai’s marketed drug, thus Haihe’s generic drug is not covered by CN1938034B.
Article 76 litigation Before the CNIPA
As discussed above, unlike the Hatch-Waxman Act in the United States, which provides a statutory framework for resolving patent disputes in the federal court system, Article 76 dispute resolution can be conducted before the CNIPA as well as the IP courts. The first patent linkage litigation decided by the CNIPA is Purdue Pharma v. Yichang Renfu Pharmaceutical Industry Limited Liability Company. In that case, as with the Chugai litigation before the Beijing IP Court, the CNIPA found in favor of the generic manufacture, holding the generic drug product manufactured by Renfu does not fall in the scope of protection of Purdue Pharma’s patents listed in the Patent Information Registration Platform.
The patents at issue include 201210135209.X (CN102657630B),4 ,201510599477.0 (CN105267170B), and 201010151552.4 (CN101812065B), which cover the drug product oxycodone hydrochloride sustained release tablets manufactured by Purdue Pharma to relieve severe pain. Renfu submitted a generic drug application for oxycodone hydrochloride sustained release tables with a Type IV certification, asserting it does not infringe the patents. Purdue Pharma filed an Article 76 proceeding with the CNIPA, requesting the CNIPA to declare Renfu’s generic product drug falls within the scope of the listed patents. On April 25, 2022, the CNIPA determined that the generics does not fall in the scope of the protection of the patents and Renfu’s generic drug product does not infringe the listed Purdue Pharma patents.
Article 76 litigation in China is fast and furious. The speed under which the Beijing IP court and CNIPA handled these cases resolves any doubt concerning whether the 9-month stay of regulatory review under Article 76 would provide sufficient time for patent infringement proceedings to play out in the IP courts and the CNIPA. Litigants should be well prepared and have a well-formed strategy before entering proceedings under Article 76.
For brand-name companies, choosing and listing strong patents in the Patent Information Registration Platform is crucial. Typically, formulation patents may not as strong as patents protecting the active pharmaceutical ingredient (API) and may be easily designed around. The success of Article 76 proceedings will depend on maintaining a strong and comprehensive patent portfolio to protect all aspects of drug development, including APIs, methods of treatment, routes of administration, combinations, and polymorphs, and the like. Such patent protection would provide the patent owner with more options to develop more robust strategies when litigating against generic companies.
For generics companies, filing a Type IV certification and asserting non-infringement of the listed patents appears to be a winning strategy under Article 76. Accordingly, generics companies should invest time and resources in early-stage product development to diligently review relevant blocking patents and potential designing around options. For example, replacing excipients in a formula of the brand-name drug product while maintaining its therapeutic efficacy may provide a winning non-infringement argument in both the IP courts and the CNIPA.
Yifan Mao is a senior associate in the Menlo Park, CA office, April Abele Isaacson is a partner in the San Francisco, CA office of Kilpatrick Townsend & Stockton, LLP.
The opinions expressed are those of the authors and do not necessarily reflect the views of the firm, its clients, or their respective affiliates. This article is for general information purposes and is not intended to be and should not be taken as legal advice.
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.